Matson noted that 2025 guidance is likely to prove conservative. Matson projected first-quarter revenue of $5.64 billion and EPS of $2.80. RBC Capital: Stryker delivered a strong exit to 2024, beating fourth-quarter consensus estimates, and issued a strong initial 2025 guide for organic sales, margins, and EPS growth. Notably, Stryker is taking steps to improve its WAMGR with the sale of its spinal implant assets and the acquisition of NARI. After today's call, Chadha is bullish on Stryker's growth durability, the trajectory for operating margin expansion, and EPS growth. Chadha projected first-quarter revenue of $5.65 billion and EPS of $2.70. Piper Sandler: Stryker also reported fourth-quarter results and guided for fiscal 2025. Both were ahead of Street expectations. More specifically, Stryker is guiding organic revenue growth of 8%-9%, which O'Brien noted as achievable, if not conservative.